ArticleBMC cancer2015
Chemopreventive effect of chalcone derivative, L2H17, in colon cancer development.
Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- In silico design, synthesis of a novel chalcone derivative and its in vitro and in vivo anticancer activity against colon cancer-induced mouse model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Acridine-Based Chalcone 1C and ABC Transporters.International journal of molecular sciences · 2025Article
- Anticancer activity mechanism of novelly synthesized and characterized benzofuran ring-linked 3-nitrophenyl chalcone derivative on colon cancer cells.Open medicine (Warsaw, Poland) · 2025Article
- Design, synthesis, and evaluation of cyclic C7-bridged monocarbonyl curcumin analogs containing anJournal of enzyme inhibition and medicinal chemistry · 2024Article
- Radiolabeled Probes from Derivatives of Natural Compounds Used in Nuclear Medicine.Molecules (Basel, Switzerland) · 2024Review
- The effect of novel nitrogen-based chalcone analogs on colorectal cancer cells: Insight into the molecular pathways.Heliyon · 2024Article
- Synthesis, Characterization, Antioxidant, and Anticancer Activity against Colon Cancer Cells of Some Cinnamaldehyde-Based Chalcone Derivatives.Biomolecules · 2024Article
- Curcumin analogues exert potent inhibition on human and rat gonadal 3β-hydroxysteroid dehydrogenases as potential therapeutic agents: structure-activity relationship and in silico docking.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Chalcones and Gastrointestinal Cancers: Experimental Evidence.International journal of molecular sciences · 2023Review
- Chalcone-3 Inhibits the Proliferation of Human Breast Cancer MDA-MB-231 Cell Line.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- A novel synthetic chalcone derivative, 2,4,6-trimethoxy-4'-nitrochalcone (Ch-19), exerted anti-tumor effects through stimulating ROS accumulation and inducing apoptosis in esophageal cancer cells.Cell stress & chaperones · 2022Article
- Novel Nitrogen-Based Chalcone Analogs Provoke Substantial Apoptosis in HER2-Positive Human Breast Cancer Cells via JNK and ERK1/ERK2 Signaling Pathways.International journal of molecular sciences · 2021Article
- Chalcone Derivatives: Role in Anticancer Therapy.Biomolecules · 2021Review
- A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells.Molecules (Basel, Switzerland) · 2021Article
- Chemopreventive effect of 4'-hydroxychalcone on intestinal tumorigenesis inOncology letters · 2021Article
- Impacts of exercise interventions on different diseases and organ functions in mice.Journal of sport and health science · 2020Review
- A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products.Cancer cell international · 2020Article
- The novel chalcone analog L2H17 protects retinal ganglion cells from oxidative stress-induced apoptosis.Neural regeneration research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColon cancer is the third most commonly diagnosed cancer and the second leading cause of cancer mortality worldwide. Chalcone and its derivatives are reported to exhibit anti-cancer effects in several cancer cell lines, including colon cancer cells. In addition, chalcones have advantages such as poor interaction with DNA and low risk of mutagenesity. In our previous study, a group of chalcone derivatives were synthesized and exhibited strong anti-inflammatory activities. In this study, we evaluated the anti-cancer effects of the chalcone derivative, L2H17, in colon cancer cells.
methodsThe cytotoxicities of L2H17 on various colon cancer cell lines were investigated by MTT and clonogenic assay. Cell cycle and apoptosis analysis were performed to evaluate the molecular mechanism of L2H17-mediated inhibition of tumor growth. Also, scratch wound and matrigel invasion experiments were performed to estimate the cell migration and invasion after L2H17 treatment. Finally, we observed the anti-colon cancer effects of L2H17 in vivo.
resultsOur data show that compound L2H17 exhibited selective cytotoxic effect on colon cancer cells, via inducing G0/G1 cell cycle arrest and apoptosis in CT26.WT cells. Furthermore, L2H17 treatment decreased cell migration and invasion of CT26.WT cells. In addition, L2H17 possessed marked anti-tumor activity in vivo. The molecular mechanism of L2H17-mediated inhibition of tumor promotion and progression were function through inactivated NF-κB and Akt signaling pathways.
conclusionsAll these findings show that L2H17 might be a potential growth inhibitory chalcones derivative for colon cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.